论文部分内容阅读
本文观察了用乐腹康胶囊活菌制剂对正常人体肠道的双歧杆菌、乳杆菌、大肠杆菌等的影响。结果显示口服乐腹康胶囊活菌制剂后，对正常人体肠道菌群有短暂（1～2天）抑制作用，而后对厌氧菌中的双歧杆菌、乳杆菌有明显促进生长的作用，双歧杆菌在服药前平均为5．06×108±1．03×108／g，服药后10天升至18．73×108±1．43×108／g，增长3．70倍，差异有显著意义（P＜0．001）。乳杆菌服药前平均数为2．74×108±0．25×108／g，服药后10天升至5．07×108×1．21×108／g，增长1．85倍（P＜0．01）。而对需氧的大肠杆菌和其它肠道球菌有持续的抑制作用，大肠杆菌服药前平均数为3．42×108／g±0．21×108／g，服药后10天降至1．05×108±0．09×108／g，仅为原来的30％（P＜0．05）。
In this paper, we observed the effect of Lactobacillus capsules live bifidobacteria on bifidobacteria, lactobacilli and Escherichia coli in normal human intestinal tract. The results showed that oral Lactobacillus capsules live viable preparations, the normal human intestinal flora has a short (1-2 days) inhibition, and then the anaerobic bacteria Bifidobacterium, Lactobacilli significantly promote the growth of the role, Bifidobacterium averaged 5.06 × 108 ± 1.03 × 108 / g before taking the medicine and rose to 18.73 × 108 ± 1.43 × 108 / g within 10 days after taking the medicine, increased by 3.70 times, the difference was Significant (P <0.001). Lactobacillus before taking the average number of 2.74 × 108 ± 0.25 × 108 / g, 10 days after taking the drug rose to 5.07 × 108 × 1.21 × 108 / g, an increase of 1.85 times (P <0 .01). While on aerobic E. coli and other enterococci have a sustained inhibition of E. coli before taking the average number of 3.42 × 108 / g ± 0.21 × 108 / g, 10 days after taking to 1.05 × 108 ± 0.09 × 108 / g, only the original 30% (P <0.05).